AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27009579 — intervention group
Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (SBP) in participants aged 80 years
Number of subjects: 1973
Study 27009579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status indicators (serum albumin, frequency of going outdoors) in participants aged 80 years
Number of subjects: 1973
Study 25684233 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanoxerine 200 mg
Number of subjects: 104
Study 25684233 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanoxerine 300 mg
Number of subjects: 104
Study 25684233 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanoxerine 400 mg
Number of subjects: 104
Study 25684233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 24172120 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 g/kg)
Number of subjects: 61
Study 24172120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20859556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant-supported overdentures (IOD)
Number of subjects: 1
Study 20859556 — intervention group
Group type: COMPARATOR
Intervention: Denture abstention
Number of subjects: 1
Study 19038680 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ON (Cardiac Resynchronization Therapy)
Number of subjects: 610
Study 19038680 — intervention group
Group type: COMPARATOR
Intervention: CRT-OFF (Control)
Number of subjects: 610
Study 16166875 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Advance Care Planning (PC-ACP)
Number of subjects: 32
Study 16166875 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study 12849769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional semantic battery
Number of subjects: 21
Study 12849769 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic semantic priming task
Number of subjects: 21
Study 12849769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional semantic tasks
Number of subjects: 21
Study 12849769 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic semantic tasks
Number of subjects: 21
Study 10623399 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 check included in the mailer
Number of subjects: 400
Study 10623399 — intervention group
Group type: COMPARATOR
Intervention: No compensation
Number of subjects: 400
Study 10623399 — intervention group
Group type: COMPARATOR
Intervention: Telephone follow-up
Number of subjects: 400
Study 10623399 — intervention group
Group type: COMPARATOR
Intervention: No follow-up call
Number of subjects: 400
Study 8664205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigilance-plus-memory training
Number of subjects: 40
Study 8664205 — intervention group
Group type: COMPARATOR
Intervention: Vigilance training alone
Number of subjects: 40
Study 2309544 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms/kg
Number of subjects: 30
Study 2309544 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study 506742 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg zimelidine
Number of subjects: 3
Study 506742 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg imipramine
Number of subjects: 3
Study 506742 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg chlorimipramine
Number of subjects: 3
Study 31336289 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual LDCT screening
Number of subjects: 2376
Study 31336289 — intervention group
Group type: COMPARATOR
Intervention: Biennial LDCT screening
Number of subjects: 2376
Study 28899412 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet with detailed information on the benefits and harms of screening
Number of subjects: 400
Study 28899412 — intervention group
Group type: COMPARATOR
Intervention: Standard leaflet that does not mention harms
Number of subjects: 400
Study 25886483 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture, electroacupuncture, and intradermal acupuncture
Number of subjects: 80
Study 25886483 — intervention group
Group type: COMPARATOR
Intervention: Mock transcutaneous electrical nerve stimulation and sham intradermal acupuncture
Number of subjects: 80
Study 23743879 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent support programme for caregivers (2-week rehabilitation period)
Number of subjects: 135
Study 23743879 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 135
Study 23743879 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent support programme for caregivers
Number of subjects: 135
Study 21167235 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin
Number of subjects: 0
Study 21167235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin alone)
Number of subjects: 0
Study 19700936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol patch (TP) at 2mg/day plus ICS
Number of subjects: 89
Study 19700936 — intervention group
Group type: COMPARATOR
Intervention: Slow-release theophylline (SRT)
Number of subjects: 89
Study 19700936 — intervention group
Group type: COMPARATOR
Intervention: Leukotriene receptor antagonist (LTRA)
Number of subjects: 89
Study 19700936 — intervention group
Group type: COMPARATOR
Intervention: Control group (ICS alone)
Number of subjects: 89
Study 17760494 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (intravenous injection)
Number of subjects: 0
Study 17760494 — intervention group
Group type: COMPARATOR
Intervention: Codeine (intramuscular route)
Number of subjects: 0
Study 15010197 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Rating Scale (VRS)
Number of subjects: 20
Study 15010197 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 20
Study 15010197 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical Rating Score (NRS)
Number of subjects: 20
Study 11251433 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target-concentration infusion (4 mg.l‐1)
Number of subjects: 50
Study 11251433 — intervention group
Group type: COMPARATOR
Intervention: 8% sevoflurane inhalation with 50% nitrous oxide
Number of subjects: 50
Study 9758026 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lateral rotational therapy (CLRT) <40 degrees
Number of subjects: 13
Study 9758026 — intervention group
Group type: COMPARATOR
Intervention: Control periods (supine and stationary)
Number of subjects: 13
Study 8993096 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine (0.4-0.8 g/kg/day) added to neuroleptics
Number of subjects: 0
Study 2248106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum users
Number of subjects: 1096
Study 2248106 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum non-users
Number of subjects: 1096
Study 2248106 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstainers
Number of subjects: 1096
Study 2248106 — intervention group
Group type: COMPARATOR
Intervention: Relapsers
Number of subjects: 1096
Study 2248106 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall weight change
Number of subjects: 1096
Study 2248106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette consumption
Number of subjects: 1096
Study 2248106 — intervention group
Group type: COMPARATOR
Intervention: Abstainers who relapsed vs maintained abstinence
Number of subjects: 1096
Study 6448210 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque (metrizamide)
Number of subjects: 0
Study 6448210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix (ioxaglic acid)
Number of subjects: 0
Study 30681717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive approach (cognitive load, immediate response)
Number of subjects: 199
Study 30681717 — intervention group
Group type: COMPARATOR
Intervention: Deliberative approach (no cognitive load, careful thought)
Number of subjects: 199
Study 30681717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive approach
Number of subjects: 199
Study 30681717 — intervention group
Group type: COMPARATOR
Intervention: Deliberative approach
Number of subjects: 199
Study 28522757 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle tracking ultrasound
Number of subjects: 13
Study 28522757 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound techniques
Number of subjects: 13
Study 26214848 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report adherence assessment
Number of subjects: 696
Study 26214848 — intervention group
Group type: COMPARATOR
Intervention: Smart blister packs adherence assessment
Number of subjects: 696
Study 23683608 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACTZ) 500 mg administered intravenously to healthy subjects (HV)
Number of subjects: 15
Study 23683608 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACTZ) 500 mg administered intravenously to peritoneal dialysis patients (CAPD)
Number of subjects: 15
Study 20623036 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate occlusal loading
Number of subjects: 40
Study 20623036 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate non-occlusal loading
Number of subjects: 40
Study 20623036 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 20623036 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post-extractive implants
Number of subjects: 40
Study 20623036 — intervention group
Group type: COMPARATOR
Intervention: Delayed implants
Number of subjects: 40
Study 18997540 — intervention group
Group type: EXPERIMENTAL
Intervention: SofLens 38
Number of subjects: 24
Study 18997540 — intervention group
Group type: COMPARATOR
Intervention: OASYS
Number of subjects: 24
Study 18997540 — intervention group
Group type: COMPARATOR
Intervention: ADVANCE
Number of subjects: 24
Study 18997540 — intervention group
Group type: COMPARATOR
Intervention: NIGHT & DAY
Number of subjects: 24
Study 16618980 — intervention group
Group type: EXPERIMENTAL
Intervention: nateglinide (270 mg/day)
Number of subjects: 29
Study 16618980 — intervention group
Group type: COMPARATOR
Intervention: voglibose (0.6 mg/day)
Number of subjects: 29
Study 16618980 — intervention group
Group type: EXPERIMENTAL
Intervention: nateglinide
Number of subjects: 29
Study 16618980 — intervention group
Group type: COMPARATOR
Intervention: voglibose
Number of subjects: 29
Study 14743120 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (Group A)
Number of subjects: 70
Study 14743120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Anesthesia (Group B)
Number of subjects: 70
Study 11201870 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepromatous patients without ENL
Number of subjects: 130
Study 11201870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculoid leprosy patients
Number of subjects: 130
Study 11201870 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ENL
Number of subjects: 130
Study 11201870 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepromatous patients with ENL
Number of subjects: 130
Study 8725991 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg)
Number of subjects: 15
Study 1683365 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 55
Study 1683365 — intervention group
Group type: COMPARATOR
Intervention: High-flow face mask oxygen therapy (control)
Number of subjects: 55
Study 7054205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 grams of aspirin (low dose)
Number of subjects: 182
Study 7054205 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 grams of aspirin (high dose)
Number of subjects: 182
Study 31279331 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf-Motor-Function-Test-Orthopaedic (WMFT-O)
Number of subjects: 56
Study 31279331 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability of the Arm, Shoulder and Hand (DASH)
Number of subjects: 56
Study 28987723 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100mg/day)
Number of subjects: 50
Study 28987723 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 50
Study 26514303 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4mg)
Number of subjects: 88
Study 26514303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25mg)
Number of subjects: 88
Study 26514303 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (1.5mg)
Number of subjects: 88
Study 26514303 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 88
Study 24720535 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (S)
Number of subjects: 39
Study 24720535 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe (S+E)
Number of subjects: 39
Study 24720535 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo run-in)
Number of subjects: 39
Study 22718810 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/day + Azelnidipine 16 mg/day
Number of subjects: 0
Study 22718810 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 8 mg/day + Amlodipine 5 mg/day
Number of subjects: 0
Study 19011838 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall
Number of subjects: 16
Study 19011838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17586304 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplementation
Number of subjects: 220
Study 17586304 — intervention group
Group type: COMPARATOR
Intervention: WHO standard vitamin A supplementation
Number of subjects: 220
Study 15482975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0
Study 15482975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11457420 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 14
Study 11457420 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 14
Study 9738674 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (CLB)
Number of subjects: 235
Study 9738674 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 235
Study 9738674 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 235
Study 8302071 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml/min
Number of subjects: 62
Study 8302071 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 ml/min
Number of subjects: 62
Study 8302071 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml/min
Number of subjects: 62
Study 8302071 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml/min
Number of subjects: 62
Study 8302071 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml/min
Number of subjects: 62
Study 8302071 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml/min
Number of subjects: 62
Study 8302071 — intervention group
Group type: COMPARATOR
Intervention: Low flow groups (50, 75, 100 ml/min)
Number of subjects: 62
Study 8302071 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow groups (200, 300 ml/min)
Number of subjects: 62
Study 3291548 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure reducing medical therapy
Number of subjects: 15
Study 3291548 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 15
Study 31774464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg)
Number of subjects: 32
Study 31774464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg or 10 mg/kg)
Number of subjects: 32
Study 31340226 — intervention group
Group type: EXPERIMENTAL
Intervention: PUI + NaOCl
Number of subjects: 60
Study 31340226 — intervention group
Group type: EXPERIMENTAL
Intervention: PUI + CHXg+SS
Number of subjects: 60
Study 31340226 — intervention group
Group type: EXPERIMENTAL
Intervention: PUI + CHXs
Number of subjects: 60
Study 31340226 — intervention group
Group type: EXPERIMENTAL
Intervention: PUI + SS
Number of subjects: 60
Study 28143504 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Therapeutic Alliance group (counseling and guidance with emphasis on therapeutic alliance and empathy)
Number of subjects: 222
Study 28143504 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Treatment group (same information and counseling with limited interaction with the therapist)
Number of subjects: 222
Study 28143504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 222
Study 26286486 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised email invitation
Number of subjects: 344
Study 26286486 — intervention group
Group type: COMPARATOR
Intervention: Generic email invitation
Number of subjects: 344
Study 23167442 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancy (glass of beer/wine)
Number of subjects: 80
Study 23167442 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 80
Study 23167442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco devaluation (health warnings and smoking satiety)
Number of subjects: 80
Study 23167442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominal Pavlovian to instrumental transfer (PIT) test
Number of subjects: 80
Study 23167442 — intervention group
Group type: EXPERIMENTAL
Intervention: Reacquisition test with direct feedback from outcomes
Number of subjects: 80
Study 21238572 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of RIX4414
Number of subjects: 0
Study 21238572 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized formulation of RIX4414
Number of subjects: 0
Study 21238572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18617536 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy plus chemotherapy
Number of subjects: 330
Study 18617536 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 330
Study 17314754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus docetaxel
Number of subjects: 150
Study 17314754 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine
Number of subjects: 150
Study 12928049 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-stimulated blood cells from AD patients
Number of subjects: 32
Study 12928049 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-stimulated blood cells from mild and moderate AD patients
Number of subjects: 32
Study 12928049 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1beta, IL-6, and TNF-alpha secretion
Number of subjects: 32
Study 12928049 — intervention group
Group type: COMPARATOR
Intervention: Age-related controls
Number of subjects: 32
Study 10689150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-nasal live attenuated influenza vaccine (Livac)
Number of subjects: 0
Study 10689150 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (Ivac)
Number of subjects: 0
Study 10689150 — intervention group
Group type: COMPARATOR
Intervention: Baculovirus recombinant vaccine or adjuvanted Ivac
Number of subjects: 0
Study 9337824 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 135
Study 9337824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no long-term oxygen therapy)
Number of subjects: 135
Study 8450436 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK with centration measured from the pupillary center
Number of subjects: 49
Study 8450436 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK with centration measured from the corneal vertex
Number of subjects: 49
Study 8450436 — intervention group
Group type: EXPERIMENTAL
Intervention: Right eyes
Number of subjects: 49
Study 8450436 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentration
Number of subjects: 49
Study 2880596 — intervention group
Group type: EXPERIMENTAL
Intervention: Etintidine 300 mg b.d.
Number of subjects: 20
Study 2880596 — intervention group
Group type: EXPERIMENTAL
Intervention: Etintidine 400 mg b.d.
Number of subjects: 20
Study 2880596 — intervention group
Group type: EXPERIMENTAL
Intervention: Etintidine 300 mg nocte.
Number of subjects: 20
Study 2880596 — intervention group
Group type: EXPERIMENTAL
Intervention: Etintidine 600 mg nocte.
Number of subjects: 20
Study 2880596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg nocte.
Number of subjects: 20
Study 2880596 — intervention group
Group type: EXPERIMENTAL
Intervention: Etintidine 300 mg b.d. and 400 mg b.d.
Number of subjects: 20
Study 2880596 — intervention group
Group type: EXPERIMENTAL
Intervention: Etintidine (any dose) at bedtime.
Number of subjects: 20
Study 2880596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30267093 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% proparacaine eye drops (anesthesia trial)
Number of subjects: 10
Study 30267093 — intervention group
Group type: COMPARATOR
Intervention: Normal saline drops (placebo trial)
Number of subjects: 10
Study 28033375 — intervention group
Group type: EXPERIMENTAL
Intervention: Uremic solutes concentrations at baseline and after one year of follow-up
Number of subjects: 80
Study 28033375 — intervention group
Group type: EXPERIMENTAL
Intervention: Uremic solutes concentrations
Number of subjects: 80
Study 24464845 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental pump speed (testinc) with a mean increase of 1486±775 rpm during exercise testing.
Number of subjects: 14
Study 24464845 — intervention group
Group type: COMPARATOR
Intervention: Fixed pump speed (testfix) during exercise testing.
Number of subjects: 14
Study 23322144 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 23 mg/day
Number of subjects: 5400000
Study 23322144 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 10 mg/day
Number of subjects: 5400000
Study 20438292 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human BNP (rhBNP)
Number of subjects: 149
Study 20438292 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 149
Study 17388755 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic inhalation profiles with low flow segments of 300 mL to 900 mL inhaled volume at 8 L/min
Number of subjects: 0
Study 17388755 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic inhalation profiles
Number of subjects: 0
Study 15516367 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO(3) ingestion (3 mmol/kg body weight)
Number of subjects: 7
Study 15516367 — intervention group
Group type: COMPARATOR
Intervention: Control study (no NaHCO(3) ingestion)
Number of subjects: 7